Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Your Edge In Biotech.
Frontpoints Latest Articles
Biotech Legend Retires, Jazz Buys Glioma Drug, & FDA Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Bluebird Fire Sale, Regeneron’s Gene Therapy for Deafness, & Eikon Raises a Bundle
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Defend Young Scientists
Biotech thrives on the creative dynamism of young scientists. Always has. Young scientists are under pressure. NIH grants are on hold. If the NIH budget... Read More
Defend the FDA
We need a competent, well-supported, tough and independent food and drug regulator in this country. We need that independent cop on the beat so we... Read More
RFK Jr. in Power, NIH and FDA on the Chopping Block, & Interest Rates Loom Large
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Defend the NIH
Too many people don’t believe anymore in the American Dream. But if you can’t dream big, you can’t accomplish big things. Today, the National Institutes... Read More
Billion Cells Project, Alumis Merges, BMS Cuts Deeper
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More